Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCAT 2023 | Bone Marrow Quality Index to assess the safety of HSCT in thalassemia

Lawrence Faulkner • 26 Oct 2023
ASCAT 2023
Non-Malignant Thalassemia

Lawrence Faulkner, MD, Cure2Children Foundation, Florence, Italy, discusses his recent publication on the use of a bone marrow quality index to predict graft-versus-host disease (GvHD) in hematopoietic stem cell transplantation (HSCT) for thalassemia. This interview was held at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Lawrence Faulkner

0:59
The future of SCD and thalassemia HSCT: partially matched donors
Lawrence Faulkner • 26 Oct 2023
0:54
The barriers to gene therapy implementation for treating SCD in low- and middle-income countries
Lawrence Faulkner • 26 Oct 2023
2:30
Cure2Children: delivering transplant therapy for SCD and thalassemia in developing countries
Lawrence Faulkner • 26 Oct 2023

Related Videos

1:09
Improving the mental health and psychological resilience of patients with SCD
Marsha Treadwell • 29 Apr 2024
4:38
Patient selection for investigating the use of heparin as thromboprophylaxis in pregnancy
Beverley Hunt • 29 Apr 2024
2:34
A national physician survey investigating the management of pulmonary thromboembolism in pregnancy
Giulia Simini • 29 Apr 2024
1:39
Considering the use of gene therapy in severe inherited thrombophilia
Beverley Hunt • 29 Apr 2024
The content of VJHemOnc is intended for healthcare professionals